These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17064228)

  • 21. Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review.
    Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):761-767. PubMed ID: 31540558
    [No Abstract]   [Full Text] [Related]  

  • 22. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.
    Li H; Chintalapudi SR; Jablonski MM
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1103-1114. PubMed ID: 28816076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
    Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging therapies for neovascular age-related macular degeneration: state of the art.
    Donati G
    Ophthalmologica; 2007; 221(6):366-77. PubMed ID: 17947822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL; Colquitt J; Clegg AJ; Jones J
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of choroidal neovascularization in high myopia.
    Montero JA; Ruiz-Moreno JM
    Curr Drug Targets; 2010 May; 11(5):630-44. PubMed ID: 20196722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].
    Pauleikhoff D; Bornfeld N; Gabel VP; Holz F; Roider H; ; ;
    Klin Monbl Augenheilkd; 2005 May; 222(5):381-8. PubMed ID: 15912454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Status of therapies in development for the treatment of age-related macular degeneration.
    Hunt DW; Margaron P
    IDrugs; 2003 May; 6(5):464-9. PubMed ID: 12789601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK; Moon HJ
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
    Tolentino MJ; Dennrick A; John E; Tolentino MS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.
    Wickens J; Blinder KJ
    Drug Saf; 2006; 29(3):189-99. PubMed ID: 16524319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.
    Noël A; Jost M; Lambert V; Lecomte J; Rakic JM
    Trends Mol Med; 2007 Aug; 13(8):345-52. PubMed ID: 17644433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
    Tamaki Y
    Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.